Bull, Bear & Beyond – IRLAB Therapeutics: executive interview

Bull, Bear & Beyond – IRLAB Therapeutics: executive interview

IRLAB Therapeutics — 2 videos in collection

More on this equity

IRLAB Therapeutics (OMX: IRLAB-A) is a Sweden-based biopharma company focused on the development of novel treatments for neurodegenerative diseases, with a particular focus on Parkinson’s disease (PD). The company has a highly active pipeline, with assets spanning all stages of clinical development, from preclinical programmes through to its lead asset, mesdopetam, which is Phase III-ready.

Listen on your preferred podcast player below:

About Bull, Bear & Beyond: Each episode features candid conversations with senior executives and from our own team of experts from across industries, exploring strategy, innovation, and the opportunities shaping their markets and 60-second pieces are a compressed summary of content designed to convey our message in a single, easily shareable hit.

< Previous

Next >

You may also be interested in these:

Healthcare

23.09.24

Bull, Bear & Beyond – IRLAB Therapeutics: executive interview